Obesity Drug Hit Makes Novo Nordisk More Valuable Than Nestle
- Danish firm is major player in diabetes and obesity treatments
- Company has ‘exceeded expectations,’ its CEO said Thursday
This article is for subscribers only.
It’s the Wegovy effect.
The blockbuster weight-loss drug, a hit with Hollywood and Silicon Valley celebrities, has more than doubled the market value of Novo Nordisk A/S since 2021 and looks set to be a cash cow for the Danish firm for years to come.